Distinct cerebrospinal fluid amyloid‐beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia

Mild alterations in cognitive function are present in normal aging and severe cognitive alterations are a hallmark of Alzheimer's disease (AD). Cognitive deficits are prevalent in patients with schizophrenia (SCZ) and worsen with old age. We recently reported that elderly SCZ patients show reduced levels of amyloid‐beta (Aβ)1–42 in cerebrospinal fluid (CSF). To further clarify the role of Aβ in cognitive decline, we analyzed the whole panel of CSF Aβ isoforms in elderly SCZ patients as well as in sporadic AD using SELDI TOF MS. The immunoproteomic study revealed, in all analyzed CSF samples, the presence of 15 different Aβ peptides. In CSF from SCZ, we detected an overall strong reduction of almost all Aβ species while in sporadic AD Aβ1–42 was the only peptide reduced. A significant independent association between Aβ1–40 levels and global cognition was found in SCZ. In addition, in SCZ patients, duration of therapy was positively associated with soluble amyloid precursor protein alpha levels, the total amount of CSF Aβ and the most abundant Aβ1–40 isoform. These data suggests a dysmetabolism of amyloid precursor protein in older SCZ patients. Thus, the quite comparable reduction of CSF Aβ1–42 in AD and in elderly SCZ patients reflects different pathophysiological dynamics in ageing brain.

[1]  K. Blennow,et al.  Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. , 2011, Current pharmaceutical design.

[2]  P. Thompson,et al.  Alzheimer's CSF markers in older schizophrenia patients , 2011, International journal of geriatric psychiatry.

[3]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[4]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  Huaxi Xu,et al.  APP processing in Alzheimer's disease , 2011, Molecular Brain.

[6]  Simone Lista,et al.  Optimization protocol for amyloid‐β peptides detection in human cerebrospinal fluid using SELDI TOF MS , 2010, Proteomics. Clinical applications.

[7]  P. Thompson,et al.  In Vivo Neuropathology of Cortical Changes in Elderly Persons with Schizophrenia , 2009, Biological Psychiatry.

[8]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[9]  R. Nitsch,et al.  Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology , 2004, Neurodegenerative Diseases.

[10]  P. Lewczuk,et al.  The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide , 2003 .

[11]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[12]  V. Haroutunian,et al.  Amyloid β Pathology in Alzheimer’s Disease and Schizophrenia , 2003 .

[13]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[14]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[15]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[16]  E. Susser,et al.  Senile degeneration and cognitive impairment in chronic schizophrenia. , 1998, The American journal of psychiatry.

[17]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[18]  J. Trojanowski,et al.  Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. , 1998, Archives of general psychiatry.

[19]  K. Davis,et al.  Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. , 1998, Archives of general psychiatry.

[20]  M. Tabaton,et al.  Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.

[21]  J. Trojanowski,et al.  Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. , 1996, The American journal of pathology.

[22]  Jane S. Paulsen,et al.  Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. , 1994, Archives of general psychiatry.

[23]  J. Kleinman,et al.  A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia , 1993, Psychiatry Research.

[24]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[26]  P. Rossini,et al.  Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. , 2009, Journal of Alzheimer's disease : JAD.